Sanofi and Advent completed negotiations for the acquisition of Zentiva

| By | Generics, Pharmaceutical Deal, Sanofi, Zentiva
0
67

Sanofi and Advent International have finished negotiations for the acquisition of Zentiva, Sanofi’s European generics business, by Advent and the companies have signed a Share Purchase Agreement worth €1.9 billion (enterprise value). Earlier the companies announced that they had entered into negotiations.

The signing of this Share Purchase Agreement marks a critical step on the way to the closing of the deal and the transfer of the Zentiva business to Advent, that is anticipated during the course of the fourth quarter of 2018. The transaction remains subject to the approval of the competent regulatory authorities.

Zentiva is an agile healthcare player providing reliable access across Europe to a broad generics portfolio covering a multitude of therapeutic areas. Headquartered in Prague, Zentiva reaches over 40 million patients in 25 European countries, operating throughout a large marketplace with attractive levels of both short- and midterm growth outlook. Zentiva stands apart with the expertise and agility to tailor customer-centric solutions in the three European generics market archetypes (pharmacy, physician and tender/wholesaler). Zentiva’s integrated value chain and pan-European commercial footprint makes it one of the largest generics players in Europe. Operating to the highest quality and safety standards, Zentiva’s flexible manufacturing facilities in Prague and Bucharest work with partners to produce and distribute more than 350 million packs each year.

Founded in 1984, Advent International is one of the largest and most experienced global private equity investors. The firm has invested in over 335 private equity transactions in 41 countries and as of March 31, 2018, it had €33 billion in assets under management. With offices on four continents, Advent has established a globally integrated team of over 190 investment professionals across North America, Europe, Latin America and Asia. The firm focuses on investments in five core sectors, including business and financial services; healthcare; industrial; retail, consumer and leisure; and technology, media and telecom.

SOURCE: sanofi
SHARE
GMP news
Pharmaceutical industry News and events. Technology transfer and contract manufacturing of medicines.